Trial Profile
The study evaluating the efficacy and safety of sorafenib in patients with differentiated thyroid cancer not amendable to radioactive iodine therapy and other alternative treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Mar 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- Acronyms RAI-skip
- 07 Mar 2019 Status changed from active, no longer recruiting to completed.
- 04 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Nov 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.